{
    "info": {
        "nct_id": "NCT03398655",
        "official_title": "A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer",
        "inclusion_criteria": "1. Female patients ≥18 years of age\n2. Histologically confirmed epithelial ovarian cancer and documented disease.\n3. Patients must have platinum-resistant disease\n4. Patients must have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment.\n5. ECOG PS 0-1.\n6. Adequate hematological functions:\n\n   * ANC ≥ 1000/mm3\n   * PLT ≥ 100,000/mm3\n   * PT and PTT (seconds) < 1.2 X ULN. Patients who are anticoagulated do not need to meet criteria for PT and PTT.\n7. Patients who are known to carry a BRCA mutation may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment).\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Non-epithelial tumors (Carcino-sarcomas are excluded)\n2. Ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.\n3. History of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.\n4. Previous ovarian cancer treatment with >5 anticancer regimens.\n5. Any prior radiotherapy to the pelvis or whole abdomen.\n6. Inadequate liver function, defined as serum creatinine > ULN, unless calculated creatinine clearance > 50ml/min (by Cockroft & Gault formula):\n\n   * Serum (total) bilirubin > ULN (Exception: documented Gilbert's disease patients can be enrolled)\n   * Alkaline phosphatase, AST/SGOT or ALT/SGPT ≥2.5 x ULN (or ≥ 5 x ULN in the presence of liver metastases).\n7. Inadequate renal function, defined as:\n\n   * Serum creatinine > ULN OR\n   * Calculated creatinine clearance < 50ml/min (by Cockroft & Gault formula)\n8. New York Heart Association (NYHA) Grade II or greater congestive heart failure\n9. History of myocardial infarction or unstable angina within 6 months prior to day of randomization.\n10. History of stroke or transient ischemic attack within 6 months prior to day of randomization.\n11. Patient with proliferative and/or vascular retinopathy\n12. Known brain metastases\n13. History of hemoptysis or active GI bleeding within 6 month prior to day of randomization\n14. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).\n15. History of abdominal fistula or gastrointestinal perforation.\n16. Current signs and symptoms of bowel obstruction\n17. Uncontrolled active infection\n18. Patients who had evidence of disease progression during or up to 90 days from the last dose of the first line of platinum based therapy",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* PLT ≥ 100,000/mm3",
            "criterions": [
                {
                    "exact_snippets": "PLT ≥ 100,000/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Histologically confirmed epithelial ovarian cancer and documented disease.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed epithelial ovarian cancer",
                    "criterion": "epithelial ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients must have platinum-resistant disease",
            "criterions": [
                {
                    "exact_snippets": "platinum-resistant disease",
                    "criterion": "disease platinum resistance status",
                    "requirements": [
                        {
                            "requirement_type": "resistance status",
                            "expected_value": "platinum-resistant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patients must have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment.",
            "criterions": [
                {
                    "exact_snippets": "disease that is measurable according to RECIST 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "measurable according to RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "require chemotherapy treatment",
                    "criterion": "chemotherapy treatment requirement",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. ECOG PS 0-1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG PS 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Adequate hematological functions:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological functions",
                    "criterion": "hematological functions",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ANC ≥ 1000/mm3",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 1000/mm3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Female patients ≥18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PT and PTT (seconds) < 1.2 X ULN. Patients who are anticoagulated do not need to meet criteria for PT and PTT.",
            "criterions": [
                {
                    "exact_snippets": "PT and PTT (seconds) < 1.2 X ULN",
                    "criterion": "PT (prothrombin time)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.2,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PT and PTT (seconds) < 1.2 X ULN",
                    "criterion": "PTT (partial thromboplastin time)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.2,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are anticoagulated do not need to meet criteria for PT and PTT",
                    "criterion": "anticoagulation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Patients who are known to carry a BRCA mutation may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment).",
            "criterions": [
                {
                    "exact_snippets": "Patients who are known to carry a BRCA mutation",
                    "criterion": "BRCA mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment)",
                    "criterion": "PARP inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment intolerance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment ineligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "17. Uncontrolled active infection",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Inadequate renal function, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Inadequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Patient with proliferative and/or vascular retinopathy",
            "criterions": [
                {
                    "exact_snippets": "proliferative ... retinopathy",
                    "criterion": "proliferative retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vascular retinopathy",
                    "criterion": "vascular retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. History of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.",
            "criterions": [
                {
                    "exact_snippets": "History of other clinically active malignancy within 5 years of enrollment",
                    "criterion": "other clinically active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.",
            "criterions": [
                {
                    "exact_snippets": "Ovarian tumors with low malignant potential (i.e. borderline tumors)",
                    "criterion": "ovarian tumor malignant potential",
                    "requirements": [
                        {
                            "requirement_type": "malignant potential",
                            "expected_value": "low"
                        }
                    ]
                },
                {
                    "exact_snippets": "clear cell carcinomas",
                    "criterion": "histology type",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": "clear cell carcinoma"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 1 serous tumors",
                    "criterion": "serous tumor grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "mucinous tumors",
                    "criterion": "histology type",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": "mucinous tumor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. New York Heart Association (NYHA) Grade II or greater congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association (NYHA) Grade II or greater congestive heart failure",
                    "criterion": "congestive heart failure (NYHA grade)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Previous ovarian cancer treatment with >5 anticancer regimens.",
            "criterions": [
                {
                    "exact_snippets": "Previous ovarian cancer treatment with >5 anticancer regimens",
                    "criterion": "number of previous anticancer regimens for ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Known brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Known brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Non-epithelial tumors (Carcino-sarcomas are excluded)",
            "criterions": [
                {
                    "exact_snippets": "Non-epithelial tumors",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histological type",
                            "expected_value": "non-epithelial"
                        }
                    ]
                },
                {
                    "exact_snippets": "Carcino-sarcomas are excluded",
                    "criterion": "carcinosarcoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Current signs and symptoms of bowel obstruction",
            "criterions": [
                {
                    "exact_snippets": "Current signs and symptoms of bowel obstruction",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "signs and symptoms",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum (total) bilirubin > ULN (Exception: documented Gilbert's disease patients can be enrolled)",
            "criterions": [
                {
                    "exact_snippets": "Serum (total) bilirubin > ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Exception: documented Gilbert's disease patients can be enrolled",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine > ULN OR",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine > ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance < 50ml/min (by Cockroft & Gault formula)",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance < 50ml/min (by Cockroft & Gault formula)",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft & Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).",
            "criterions": [
                {
                    "exact_snippets": "Evidence of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant coagulopathy (in the absence of therapeutic anticoagulation)",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "in the absence of therapeutic anticoagulation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Any prior radiotherapy to the pelvis or whole abdomen.",
            "criterions": [
                {
                    "exact_snippets": "Any prior radiotherapy to the pelvis",
                    "criterion": "prior radiotherapy to the pelvis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior radiotherapy to the ... whole abdomen",
                    "criterion": "prior radiotherapy to the whole abdomen",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. History of stroke or transient ischemic attack within 6 months prior to day of randomization.",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 6 months prior to day of randomization.",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... transient ischemic attack within 6 months prior to day of randomization.",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Patients who had evidence of disease progression during or up to 90 days from the last dose of the first line of platinum based therapy",
            "criterions": [
                {
                    "exact_snippets": "evidence of disease progression during or up to 90 days from the last dose of the first line of platinum based therapy",
                    "criterion": "disease progression during or up to 90 days from last dose of first line platinum based therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing of disease progression",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. History of hemoptysis or active GI bleeding within 6 month prior to day of randomization",
            "criterions": [
                {
                    "exact_snippets": "History of hemoptysis ... within 6 month prior to day of randomization",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "active GI bleeding within 6 month prior to day of randomization",
                    "criterion": "gastrointestinal bleeding",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Inadequate liver function, defined as serum creatinine > ULN, unless calculated creatinine clearance > 50ml/min (by Cockroft & Gault formula):",
            "criterions": [
                {
                    "exact_snippets": "serum creatinine > ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance > 50ml/min (by Cockroft & Gault formula)",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. History of myocardial infarction or unstable angina within 6 months prior to day of randomization.",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... within 6 months prior to day of randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to day of randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina within 6 months prior to day of randomization",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to day of randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. History of abdominal fistula or gastrointestinal perforation.",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal fistula",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... gastrointestinal perforation",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase, AST/SGOT or ALT/SGPT ≥2.5 x ULN (or ≥ 5 x ULN in the presence of liver metastases).",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase ... ≥2.5 x ULN (or ≥ 5 x ULN in the presence of liver metastases)",
                    "criterion": "Alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST/SGOT ... ≥2.5 x ULN (or ≥ 5 x ULN in the presence of liver metastases)",
                    "criterion": "AST/SGOT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT/SGPT ... ≥2.5 x ULN (or ≥ 5 x ULN in the presence of liver metastases)",
                    "criterion": "ALT/SGPT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}